This website uses cookies to enhance the user experience.
G

GENTIAN AS979 819 234

Research
Limited company
Bjørnåsveien 5 1596 MOSS, Norge

GENTIAN AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

CEO
Chairman of the board
Years since formation
26 years
since May 5, 1998
Type
Limited company
VAT registered
Yes
Number of employees
50

Ownership

Number of shares and share classes
15,000,000
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2023
118,224,537
NOK
Annual total result 2023
-1,772,208
NOK
Total equity 2023
7,050,996
NOK
Last update: Sep 12, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-

Others

NameRoleShares
B
BDO AS
Auditor-
A
AZETS INSIGHT AS
Accountant-

Top 10 individual shareholders

NameRoleShares
-
13.68 %
indirectly
-
7.81 %
indirectly
-
4.86 %
indirectly
-
3.56 %
indirectly
-
2.4 %
indirectly
-
2.4 %
indirectly
-
2.12 %
indirectly
-
1.54 %
indirectly
-
1.38 %
indirectly
-
1.35 %
indirectly
Last update: May 15, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
G
GENTIAN DIAGNOSTICS ASA
Ordinary shares
15,000,000
100 %
Last update: May 24, 2024

Group structure

Financials

in NOK

Summary

Year202320222021
Total operating income
118,224,537
96,421,779
85,257,579
Annual Total Result
-1,772,208
-13,089,728
-11,390,103
Total assets
111,011,472
124,502,834
113,541,415
Total liabilities
103,960,476
116,124,293
93,684,130
Total equity
7,050,996
8,378,542
19,857,285

P&L

Year202320222021
Total operating income
118,224,537
96,421,779
85,257,579
Total operating costs
116,361,709
105,620,895
94,189,719
Operating result
1,862,827
-9,199,116
-8,932,140
Financial income/costs
-3,635,035
-3,890,612
-2,457,963
Profit before tax
-1,772,208
-13,089,728
-11,390,103
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-1,772,208
-13,089,728
-11,390,103

Balance overview

Year202320222021
Total fixed assets
48,339,902
55,867,282
51,862,075
Total current assets
62,671,570
68,635,552
61,679,341
Total assets
111,011,472
124,502,834
113,541,415
Short term debt
18,242,608
18,463,500
15,049,813
Long term debt
85,717,869
97,660,792
78,634,317
Total liabilities
103,960,476
116,124,293
93,684,130
Contributed capital
15,000,000
15,000,000
18,898,693
Retained earnings
-7,949,004
-6,621,458
958,592
Total equity
7,050,996
8,378,542
19,857,285
Total equity and liabilities
111,011,472
124,502,834
113,541,415

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology